🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

PlasmaGen Biosciences raises Rs 150 Cr led by ViNS Bioproducts

EntrackrEntrackr · 2m ago
PlasmaGen Biosciences raises Rs 150 Cr led by ViNS Bioproducts
Medial

Snippets PlasmaGen Biosciences raises Rs 150 Cr led by ViNS Bioproducts Bengaluru-based biopharma company PlasmaGen Biosciences has raised Rs 150 crore led by ViNS Bioproducts along with participation from high-net-worth individuals, family offices, pharma entrepreneurs, and existing investors. The startup is backed by Eight Road Ventures secured the funding at a valuation of over Rs 1,500 crore. PlasmaGen has mopped up over Rs 600 crore in funding to date from Fidelity's FIL Capital Investments, Eight Roads Ventures, F-Prime Capital, and others. The proceeds will be used to scale international operations, expand the product portfolio, and strengthen manufacturing and leadership capabilities, PlasmaGen Biosciences said in a press release. Founded in 2010, PlasmaGen Biosciences focuses on producing and marketing plasma-derived therapies like Immunoglobulin, Albumin, and clotting factors to bridge India's demand-supply gap for these critical medicines, operating a modern fractionation plant in Kolar, Karnataka, and serving neurology, hematology, and critical care, aiming for self-reliance in plasma products. According to PlasmaGen, it has identified distribution partners in key export geographies and is in the process of securing regulatory approvals to begin international sales. India continues to remain a key market for the firm, which is expanding its services across hospitals and physicians through a cold-chain-backed distribution network. PlasmaGen says that it began commercial operations in 2024 at its plasma fractionation facility in Kolar, near Bengaluru. The company asserts that the setup is among only five such facilities in the country and claims that it is the first pure-play plasma biopharma player, has reported strong revenue growth since launch of operations at Kolar and is now preparing to enter overseas markets.

Exclusive: Wint Wealth to raise Series B at Rs 700 Cr valuation

EntrackrEntrackr · 1m ago
Exclusive: Wint Wealth to raise Series B at Rs 700 Cr valuation
Medial

Exclusive: Wint Wealth to raise Series B at Rs 700 Cr valuation Wint Wealth is raising Rs 120 crore (approximately $13.3 million) in its Series B funding round led by Vertex Ventures. This marks the Bengaluru-based startup’s first major fundraise in over three and a half years. Wint Wealth’s board has passed a special resolution to issue 94,047 Series B compulsory convertible preference shares at an issue price of Rs 12,804 each to raise Rs 120 crore or $13.3 million, according to the filings sourced from the Registrar of Companies. Vertex Ventures will lead the round with an investment of Rs 77.52 crore, while Unitary Fund, Eight Roads Ventures, and 3one4 Capital will infuse Rs 18.7 crore, Rs 13 crore, and Rs 8.16 crore, respectively. Zerodha’s incubation arm, Rainmatter, will also participate in the Series B with a Rs 3 crore investment. As per filings, the company plans to utilise the proceeds towards capital expenditure, marketing, and general corporate purposes. Based on Entrackr’s estimates, the wealth management startup is raising fresh capital at a post-money valuation of around Rs 707 crore (nearly $80 million). The company may raise additional capital as part of the Series B round, which could lead to changes in its valuation and shareholding structure. Post this round, Vertex Ventures will hold a 10.96% stake in Wint Wealth, while 3one4 Capital, Unitary Fund, Rainmatter, and ERVI Technology, an arm of Eight Roads Ventures, will own 8.54%, 8.32%, 2.55%, and 1.84%, respectively, according to the filings. Wint Wealth is yet to file its FY25 numbers. In FY24, the company posted Rs 17.2 crore operating revenue with a loss of Rs 18 crore.

Download the medial app to read full posts, comements and news.